A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors).
gene classifier
gene signature
predictive biomarkers
prostate cancer
tumor classification
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Jan 2020
10 Jan 2020
Historique:
received:
10
12
2019
revised:
28
12
2019
accepted:
06
01
2020
entrez:
16
1
2020
pubmed:
16
1
2020
medline:
16
1
2020
Statut:
epublish
Résumé
In this study, we extracted prostate cell-specific gene sets (metagenes) to define the epithelial differentiation status of prostate cancers and, using a deconvolution-based strategy, interrogated thousands of primary and metastatic tumors in public gene profiling datasets. We identified a subgroup of primary prostate tumors with low luminal epithelial enrichment (LumE
Identifiants
pubmed: 31936761
pii: cancers12010176
doi: 10.3390/cancers12010176
pmc: PMC7016595
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 310030-169942
Commentaires et corrections
Type : ErratumIn
Références
Nat Med. 2016 Apr;22(4):369-78
pubmed: 26928463
Nature. 2009 Sep 24;461(7263):495-500
pubmed: 19741607
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Cancer Cell. 2010 Jul 13;18(1):11-22
pubmed: 20579941
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6823-34
pubmed: 16203770
Front Oncol. 2015 Jan 12;4:375
pubmed: 25629002
Mol Cancer Res. 2019 Nov;17(11):2154-2168
pubmed: 31395667
Eur Urol. 2005 Jun;47(6):895-900
pubmed: 15925089
JAMA Oncol. 2017 Dec 1;3(12):1663-1672
pubmed: 28494073
Science. 2018 Oct 5;362(6410):91-95
pubmed: 30287662
Cold Spring Harb Perspect Med. 2019 Jun 3;9(6):
pubmed: 30291148
Nat Commun. 2013;4:2612
pubmed: 24113773
Nat Rev Cancer. 2015 Sep;15(9):563-72
pubmed: 26299593
J Natl Cancer Inst. 2008 Jun 4;100(11):815-25
pubmed: 18505969
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Cancer Cell. 2012 Feb 14;21(2):253-65
pubmed: 22340597
Nat Rev Urol. 2018 May;15(5):271-286
pubmed: 29460922
Nat Rev Clin Oncol. 2014 Jun;11(6):308-23
pubmed: 24840073
BMC Genomics. 2006 Apr 25;7:92
pubmed: 16638148
Eur Urol. 2017 Oct;72(4):509-518
pubmed: 28408174
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Elife. 2015 Sep 16;4:
pubmed: 26374986
Science. 2010 Jul 30;329(5991):568-71
pubmed: 20671189
EMBO J. 2011 May 20;30(13):2719-33
pubmed: 21602788
Brief Bioinform. 2017 May 1;18(3):426-440
pubmed: 27016391
Curr Protoc Pharmacol. 2018 Jun;81(1):e39
pubmed: 29927081
Urol Oncol. 2019 May;37(5):297.e19-297.e31
pubmed: 30827759
Cancer Cell. 2014 May 12;25(5):638-651
pubmed: 24823640
Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6
pubmed: 14711987
Mol Cell Endocrinol. 2018 Apr 15;465:73-81
pubmed: 28652170
Cancer Discov. 2019 Jun;9(6):702-710
pubmed: 30944117
Nature. 2012 Jul 12;487(7406):239-43
pubmed: 22722839
Cancer Res. 2016 Sep 1;76(17):4948-58
pubmed: 27302169
Science. 2017 Oct 20;358(6361):321-326
pubmed: 29051371
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nature. 2009 Nov 5;462(7269):108-12
pubmed: 19847166
Cell Death Dis. 2018 Feb 5;9(2):155
pubmed: 29449534
Cancer Res. 2011 Oct 15;71(20):6503-13
pubmed: 21868758
Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):E6544-52
pubmed: 26460041
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148